Scale-up path clear, but Q1 loss masks execution risk

Q1 revenue only ₹12.8 Cr suggests minimal shipments, validating 'batches' narrative

Q1 shows -53.8% NPM; zero evidence of cost structure supporting 10% at any volume yet

Prospectus cited 105 days; one analyst flagged 238-day metric from records; 85-day claim lacks corroboration

Won ₹989 Cr contract vs ~₹1,600 Cr annual market; pricing may still be below cost at ramp volumes

₹1,000+ Cr order book locked (₹989 Cr locomotive, ₹86 Cr EMU). Not present at IPO filing; now de-risked.

Post-approval, R&D center formally recognized by Department of Scientific & Industrial Research; validates indigenous IPR.

Unit 2 assembly started; planned 2-shift model in existing factory to 55/month capacity. No capex needed beyond test setups.

45-day average procurement cycle (7 days to 6 months by commodity). Three dispatches completed; payment from Railways received in 15 days each time.

1,600 new locomotives/year in India; 15,000 existing locomotives for rehabilitation; 300-500 EMUs tendered annually. All data public on Indian Railways website.

Management claimed no knowledge of cancellation. Stated active tender on CLW for 748 locomotives instead. Did not directly address cancellation reason.

Deadline is actually March/next FY for some orders. Ramping to 25 (Nov), 40 (Jan) will catch up. Extensions available if needed; Indian Railways encourages scale-up players.

L2/L1 quotes show competitive pricing, not undercut. Bulk ordering (300/200 sets) improves margin. Continuous improvement expected month-over-month once stabilized.

24 months given to design, develop, AND supply. Target design/development in 8-10 months; testing follows. Comfortably achievable within 24 months.

Last 3 dispatches completed in 85 days total (procurement to payment). Does not know source of 238-day figure; may relate to first unit only.

Won 25-26% of tendered quantity (L1/L2 positions). Indian Railways shares business among 7 winners. Safe model; competition expected but sustainable.

Confident to win 480/year consistently. Locomotive tenders growing (1,100→1,667/year historically). EMU/Vande Bharat will absorb spare capacity.

Never capitalized in past; will not capitalize in future. All R&D expensed to P&L.

Based on ramp curve: 10/month Sept, 25/month Nov, 40/month Jan-Mar = ~200 units Q3-Q4, ~560 units for FY27 at ₹1.67 Cr/unit = ~₹400 Cr.

Currently -53.8% NPM in Q1. Management acknowledges initial 1-2 months negative margins; promises improvement month-over-month. No detailed cost structure or fixed/variable breakdown provided.

Dependent on achieving stated volumes, controlling material cost inflation (electronics +10-15% globally), and labor efficiency. No price escalation clause in contracts mentioned.

Unit 1 & 2 facilities already built. 3 test setups on order; installation in 45-60 days. Existing factory sufficient for 55/month with 2-shift model.

MV has completed only 2-3 small batches pre-IPO. Targeting 40/month by January 2027 (4x ramp in 4 months). Supply chain, yield, labor productivity, quality unproven at scale.

Global electronics costs +10-15% YoY; MV has fixed-price contracts (no escalation clause mentioned). Won L1/L2 bids, not L3. Current -53.8% NPM requires dramatic turnaround to reach 10%+ at 40/month.

₹989 Cr locomotive order staggered through March 2027 and FY28. Management claims extensions available if deadline missed; relies on Indian Railways' historical lenience. Reputation & future bid eligibility at risk.

Management claims 85-day cycle from 3 dispatches; prospectus cites 105 days. Analyst flagged 238-day figure from records. Actual requirement for ₹1,000 Cr/month run = ₹200 Cr WC. IPO raised ~₹350 Cr; some used for working capital.

EMU/MEMU propulsion still in development. RDSO approval expected 15-16 months (Aug 2027). Any R&D hiccup delays entry into EMU market. Vande Bharat timeline dependent on EMU platform completion.

Siemens, Alstom, ABB (global incumbents); Medha (sole domestic incumbent until now); BHEL, Hind Rectifiers entering. Market share consolidation risk if incumbents price aggressively.